Literature DB >> 12527413

Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes.

Paul J Beisswenger1, Scott K Howell, Kenneth Smith, Benjamin S Szwergold.   

Abstract

Methylglyoxal (MG) may be an important cause of diabetic complications. Its primary source is dihydroxyacetone phosphate (DHAP) whose levels are partially controlled by glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Using a human red blood cell (RBC) culture, we examined the effect of modifying GAPDH activity on MG production. With the inhibitor koningic acid (KA), we showed a linear, concentration-dependent GAPDH inhibition, with 5 microM KA leading to a 79% reduction of GAPDH activity and a sixfold increase in MG. Changes in redox state produced by elevated pH also resulted in a 2.4-fold increase in MG production at pH 7.5 and a 13.4-fold increase at pH 7.8. We found substantial inter-individual variation in DHAP and MG levels and an inverse relationship between GAPDH activity and MG production (R=0.57, P=0.005) in type 2 diabetes. A similar relationship between GAPDH activity and MG was observed in vivo in type 1 diabetes (R=0.29, P=0.0018). Widely varying rates of progression of diabetic complications are seen among individuals. We postulate that modification of GAPDH by environmental factors or genetic dysregulation and the resultant differences in MG production could at least partially account for this observation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527413     DOI: 10.1016/s09254439(02)00219-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  37 in total

Review 1.  Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.

Authors:  Megan Jack; Douglas Wright
Journal:  Transl Res       Date:  2012-01-10       Impact factor: 7.012

2.  Is diabetes an acquired disorder of reactive glucose metabolites and their intermediates?

Authors:  T Fleming; J Cuny; G Nawroth; Z Djuric; P M Humpert; M Zeier; A Bierhaus; P P Nawroth
Journal:  Diabetologia       Date:  2012-01-22       Impact factor: 10.122

3.  The antihypertensive effect of arginine.

Authors:  Sudesh Vasdev; Vicki Gill
Journal:  Int J Angiol       Date:  2008

4.  Role of methylglyoxal in essential hypertension.

Authors:  Sudesh Vasdev; Jennifer Stuckless
Journal:  Int J Angiol       Date:  2010

5.  Featured Article: Pyruvate preserves antiglycation defenses in porcine brain after cardiac arrest.

Authors:  Gary F Scott; Anh Q Nguyen; Brandon H Cherry; Roger A Hollrah; Isabella Salinas; Arthur G Williams; Myoung-Gwi Ryou; Robert T Mallet
Journal:  Exp Biol Med (Maywood)       Date:  2017-03-31

6.  Antiglycation and cell protective actions of metformin and glipizide in erythrocytes and monocytes.

Authors:  Krishna Adeshara; Rashmi Tupe
Journal:  Mol Biol Rep       Date:  2016-02-13       Impact factor: 2.316

7.  Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity.

Authors:  Vladimir B Ritov; Elizabeth V Menshikova; Koichiro Azuma; Richard Wood; Frederico G S Toledo; Bret H Goodpaster; Neil B Ruderman; David E Kelley
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-03       Impact factor: 4.310

8.  Role of the immune system in hypertension: modulation by dietary antioxidants.

Authors:  Sudesh Vasdev; Jennifer Stuckless; Vernon Richardson
Journal:  Int J Angiol       Date:  2011-12

9.  Glyceraldehyde-3-phosphate dehydrogenase in retinal microvasculature: implications for the development and progression of diabetic retinopathy.

Authors:  Sally Madsen-Bouterse; Ghulam Mohammad; Renu A Kowluru
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-29       Impact factor: 4.799

10.  Na+/H+ exchanger 1 inhibition reverses manifestation of peripheral diabetic neuropathy in type 1 diabetic rats.

Authors:  Sergey Lupachyk; Pierre Watcho; Hanna Shevalye; Igor Vareniuk; Alexander Obrosov; Irina G Obrosova; Mark A Yorek
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-06-04       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.